Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
BioMarin: Q4 Earnings Snapshot
BioMarin: Q4 Earnings Snapshot
Associated Press Finance
Tue, February 24, 2026 at 7:08 AM GMT+9 1 min read
In this article:
BMRN
-1.81%
SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Monday reported a fourth-quarter loss of $46.6 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the San Rafael, California-based company said it had a loss of 24 cents. Earnings, adjusted for one-time gains and costs, came to 46 cents per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 25 cents per share.
The rare disease biopharmaceutical posted revenue of $874.6 million in the period, which also topped Street forecasts. Ten analysts surveyed by Zacks expected $829.7 million.
For the year, the company reported profit of $348.9 million, or $1.80 per share. Revenue was reported as $3.22 billion.
BioMarin shares have risen nearly 6% since the beginning of the year. In the final minutes of trading on Monday, shares hit $62.92, a decline of nearly 8% in the last 12 months.
This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on BMRN at
Terms and Privacy Policy
Privacy Dashboard
More Info